论文部分内容阅读
目的比较不同给药途径对于人基因重组红细胞生成素治疗血液透析患者肾性贫血。方法将52例血液透析贫血患者随机分为血液透析间期皮下注射组和血液透析下机时静脉注射组,在治疗前和治疗后的4、8、12周分别检测Hb、Rbc、Hct,以此来评估疗效。结果两组患者接受rHuEPO治疗后贫血症状都有不同程度的改善;相同剂量下皮下注射组疗效优于静脉注射组,两组比较有显著差异(P<0.05),同时皮下注射组节约药量、不良反应少。结论人基因重组红细胞生成素(rHuEPO)皮下注射优于静脉注射且具有经济实用优点。
Objective To compare the different routes of administration for the treatment of renal anemia in hemodialysis patients with recombinant human erythropoietin. Methods Fifty-two patients with hemodialysis anemia were randomly divided into intravenous hemodialysis subcutaneous injection group and hemodialysis subcutaneous injection intravenous injection group. The levels of Hb, Rbc and Hct were detected at 4, 8 and 12 weeks after treatment To assess the efficacy of this. Results After treatment with rHuEPO, the symptoms of anemia in both groups were improved to some extent. The subcutaneous injection group at the same dose had better effect than intravenous injection group (P <0.05) Adverse reactions. Conclusion Recombinant human erythropoietin (rHuEPO) is superior to intravenous injection in subcutaneous injection and has economic and practical advantages.